Masimo Announces Sleep Halo, Advanced Sleep Analysis For The Masimo W1

7/1/24 8:06:39 AM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $MASI alert in real time by email

Sleep Halo Sleep Metrics Are Based on Masimo W1's Continuous Pulse Oximetry Measurements and Advanced Halo AI Technology

Masimo (NASDAQ:MASI), today announced that the Masimo W1® Sport advanced health tracking wearable is gaining a powerful new feature: scientifically based sleep analysis with Sleep Halo™. Sleep Halo offers overnight sleep data tracking with an unmatched 70,000+ daily measurements of second-by-second continuous health data.

Get the next $MASI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MASI

Date	Price Target	Rating	Analyst
11/6/2024	$170.00	Mkt Perform → Outperform	Raymond James
6/3/2024	$126.00 → $160.00	Neutral → Overweight	Piper Sandler
4/15/2024	$148.00 → $170.00	Hold → Buy	Stifel
3/25/2024	$117.00 → $160.00	Equal Weight → Overweight	Wells Fargo
1/30/2024	$107.00 → $121.00	Buy → Hold	Jefferies
1/3/2024		Buy → Hold	Needham
11/8/2023		Outperform → Mkt Perform	Raymond James
7/18/2023	$205.00 → $120.00	Buy → Hold	Stifel

More analyst ratings

$MASI
Financials

Live finance-specific insights

Masimo Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8
11/5/24 4:05:00 PM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Masimo to Report Third Quarter 2024 Financial Results after Market Close on Tuesday, November 5
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a re
10/22/24 9:00:00 AM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Masimo Has the Right Leadership and Strategy to Drive Long-Term Value Creation
Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control Urges Stockholders to Vote "FOR" Only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company's commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company's Board of Direct
8/26/24 9:00:00 AM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Masimo to Present in the Jefferies London Healthcare Conference
Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers &
11/14/24 9:00:00 AM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Masimo to Present in Stifel 2024 Healthcare Conference
Masimo (NASDAQ:MASI) today announced that its management will participate in the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower
11/13/24 9:00:00 AM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Masimo Reports Third Quarter 2024 Financial Results
Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8
11/5/24 4:05:00 PM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$MASI
Leadership Updates

Live Leadership Updates

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
10/18/24 9:00:00 AM ET
$ENV
$LH
$MASI
$MSCI
Business Services
Consumer Discretionary
Medical Specialities
Health Care
Masimo Provides Leadership and Business Updates
Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors Reaffirms Financial Guidance for Third Quarter 2024 Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareho
9/25/24 9:00:00 AM ET
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
6/26/24 8:00:00 AM ET
$A
$ANIK
$AVNT
$MASI
Biotechnology: Laboratory Analytical Instruments
Industrials
Medical/Dental Instruments
Health Care

Masimo Announces Sleep Halo, Advanced Sleep Analysis For The Masimo W1

Chat with this insight

Recent Analyst Ratings for $MASI

$MASI Market Insights

Live Market Insights

Masimo Commenced Litigation Against Politan Capital Management In Federal Court In California Seeking To Require Politan To Correct Material Misstatements And Omissions In Politan's Proxy Materials

Proxy Advisor ISS Says Masimo Change Is 'Absolutely Necessary' In Brutal Report; Says Shareholders Should Vote For Activist Politan Capital Management's Board Nominees, Bill Jellison And Darlene Solomon

Masimo Exposes Politan's Governance Hypocrisy, Says "Over The Past Twelve Months, We Believe Politan's Quentin Koffey Has Repeatedly Acted Against The Best Interests Of Masimo And Its Stockholders"

$MASI SEC Filings

Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

Masimo Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Masimo Corporation

$MASI Financials

Live finance-specific insights

Masimo Reports Third Quarter 2024 Financial Results

Masimo to Report Third Quarter 2024 Financial Results after Market Close on Tuesday, November 5

Masimo Has the Right Leadership and Strategy to Drive Long-Term Value Creation

$MASI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Bus Dev Levy Tao covered exercise/tax liability with 14,398 shares and converted options into 30,000 shares, increasing direct ownership by 139% to 26,810 units (SEC Form 4)

SEC Form 4 filed by Interim CEO Brennan Michelle

SEC Form 4 filed by Director Scannell Timothy J

$MASI Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Masimo Corporation

Amendment: SEC Form SC 13D/A filed by Masimo Corporation

Amendment: SEC Form SC 13D/A filed by Masimo Corporation

$MASI Press Releases

Fastest customizable press release news feed in the world

$MASI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Masimo to Present in the Jefferies London Healthcare Conference

Masimo to Present in Stifel 2024 Healthcare Conference

Masimo Reports Third Quarter 2024 Financial Results

Masimo upgraded by Raymond James with a new price target

Masimo upgraded by Piper Sandler with a new price target

Masimo upgraded by Stifel with a new price target

$MASI Leadership Updates

Live Leadership Updates

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Masimo Provides Leadership and Business Updates

Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

Recent Analyst Ratings for
$MASI

$MASI
Market Insights

$MASI
SEC Filings

$MASI
Financials

$MASI
Insider Trading

$MASI
Large Ownership Changes

$MASI
Press Releases

$MASI
Analyst Ratings

$MASI
Leadership Updates